[A21-106] Nivolumab (melanoma, adjuvant) - Addendum to Commission A21-39
Last updated 16.09.2021
Project no.:
A21-106
Commission:
Commission awarded on 10.08.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection
Result of dossier assessment:
Unchanged after addendum:
- Stage IIIB/C and IV disease: hint of non-quantifiable added benefit.
- Stage IIIA disease: added benefit not proven.
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-39 | Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
Federal Joint Committee (G-BA)
2021-09-16 A G-BA decision was published.